Wedbush Initiates Coverage on Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA)

Equities research analysts at Wedbush initiated coverage on shares of Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) in a research report issued on Thursday, Marketbeat.com reports. The brokerage set an “outperform” rating and a $35.00 price target on the stock. Wedbush’s price target would suggest a potential upside of 38.83% from the company’s current price.

Other research analysts have also recently issued reports about the company. UBS Group initiated coverage on Damora Therapeutics, Inc. Common Stock in a research report on Tuesday, February 17th. They issued a “buy” rating and a $45.00 target price on the stock. Guggenheim reaffirmed a “buy” rating and issued a $40.00 price objective (up from $36.00) on shares of Damora Therapeutics, Inc. Common Stock in a research note on Tuesday, February 17th. Royal Bank Of Canada started coverage on Damora Therapeutics, Inc. Common Stock in a research note on Friday, April 24th. They issued an “outperform” rating and a $40.00 price objective on the stock. Lifesci Capital raised Damora Therapeutics, Inc. Common Stock to a “strong-buy” rating in a research note on Monday, February 2nd. Finally, Evercore started coverage on Damora Therapeutics, Inc. Common Stock in a research note on Wednesday, March 25th. They issued an “outperform” rating and a $46.00 price objective on the stock. Two equities research analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $42.00.

Damora Therapeutics, Inc. Common Stock Price Performance

Shares of NASDAQ:DMRA opened at $25.21 on Thursday. The company has a market cap of $1.55 billion, a P/E ratio of -4.52 and a beta of 1.50. Damora Therapeutics, Inc. Common Stock has a 1 year low of $2.45 and a 1 year high of $38.33. The stock’s fifty day moving average price is $25.01 and its 200-day moving average price is $25.20.

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) last posted its earnings results on Tuesday, May 12th. The company reported ($0.62) EPS for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.23). On average, sell-side analysts anticipate that Damora Therapeutics, Inc. Common Stock will post -0.95 earnings per share for the current year.

Hedge Funds Weigh In On Damora Therapeutics, Inc. Common Stock

Institutional investors have recently added to or reduced their stakes in the company. Two Sigma Investments LP bought a new stake in shares of Damora Therapeutics, Inc. Common Stock in the 3rd quarter worth about $76,000. Virtu Financial LLC bought a new stake in shares of Damora Therapeutics, Inc. Common Stock in the 3rd quarter worth about $49,000. Connective Capital Management LLC bought a new stake in shares of Damora Therapeutics, Inc. Common Stock in the 3rd quarter worth about $100,000. Sigma Planning Corp bought a new stake in shares of Damora Therapeutics, Inc. Common Stock in the 4th quarter worth about $334,000. Finally, Geode Capital Management LLC bought a new stake in shares of Damora Therapeutics, Inc. Common Stock in the 4th quarter worth about $266,000. Hedge funds and other institutional investors own 14.20% of the company’s stock.

Damora Therapeutics, Inc. Common Stock Company Profile

Galecto Inc is a clinical‐stage biotechnology company developing small‐molecule therapies that target key pathways involved in fibrotic and malignant diseases. The company’s research focuses on inhibiting galectin‐3, an extracellular carbohydrate‐binding protein implicated in inflammation, fibrosis and tumor progression, as well as lysyl oxidase‐like 2 (LOXL2), an enzyme that crosslinks collagen and elastin in fibrotic tissue.

Its lead programs include GB0139, an inhaled galectin‐3 inhibitor in Phase II trials for idiopathic pulmonary fibrosis and other fibrosing lung diseases, and GB1211, an oral galectin‐3 inhibitor being evaluated for systemic fibrotic disorders.